1 11 0

MGAH22 (margetuximab): HER2+ Tumors

Phase 2 clinical study in patients with HER2 positive solid tumors.
Learn more: MGAH22
Learn more: ClinicalTrials.gov

Company Highlights

  • Robust pipeline in oncology and autoimmune disorders
  • Partners include Takeda, Gilead, Servier, Pfizer and Boehringer Ingelheim
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position
  • Experienced leadership and highly collaborative corporate culture 
Learn more
Home»About Us

About Us

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies.  Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases.  Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe.

Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms:


Research & Development Process at MacroGenics

The illustration below provides an overview of the research and development process at MacroGenics.  By maintaining in-house capabilities across the entire product development spectrum, we reduce our reliance on external contractors and better anticipate downstream development requirements. Furthermore, our highly collaborative approach to product development facilitates the rapid transition of programs through the development process. 
 


Product Pipeline Summary

MacroGenics has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. 

In oncology, MacroGenics is conducting Phase 2 clinical development of MGAH22 (or margetuximab).  MGAH22 is the first Fc-modified anti-cancer mAb produced from the company’s proprietary Fc optimization technology and targets tumors that over-express the HER2 oncoprotein, potentially including breast, bladder and gastric cancers.  In mid-2011, MacroGenics began clinical development of its second anti-cancer mAb, MGA271, which recognizes a novel target (B7-H3), which is expressed on several solid tumor types.  MGA271 is a humanized, Fc-optimized mAb that is being studied for the treatment of multiple solid tumors, potentially including prostate, renal and pancreatic cancers as well as melanomas.  MacroGenics’ earlier stage oncology pipeline includes multiple programs for which the company expects to select clinical development candidates over the next several years.

The company’s lead autoimmune program, teplizumab, is an anti-CD3 antibody being developed for the prevention and treatment of early onset type 1 diabetes.  In June 2011, MacroGenics announced the publication in The Lancet of results from Protégé, a Phase 3 clinical study of teplizumab in type 1 diabetes. Exploratory, post-hoc analyses suggest that teplizumab, an anti-CD3 monoclonal antibody, when used in a full dose regimen may preserve C-peptide and increase the percentage of patients requiring very low doses of insulin compared to those on placebo. In addition, these analyses identified certain subpopulations to be studied in future trials.

MacroGenics is also pursuing development of its own proprietary molecules for the treatment of inflammatory disease.

MacroGenics’ infectious disease portfolio includes several antibody-based therapeutics for the treatment of infectious diseases from pathogens, including Dengue, smallpox and H5N1.


View full Product Pipeline